Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A major obstacle in cancer gene therapy is selective tumor delivery. Previous studies have suggested that genetically engineered anaerobes of the genus Clostridium might be gene therapy vectors because of their ability to proliferate selectively in the hypoxic/necrotic regions common to solid tumors. However, the tumor colonization efficiency of the strain previously used was insufficient to produce any antitumor effect. Here we describe for the first time the successful transformation of C. sporogenes, a clostridial strain with the highest reported tumor colonization efficiency, with the E. coli cytosine deaminase (CD) gene and show that systemically injected spores of these bacteria express CD only in the tumor. This enzyme can convert the nontoxic prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU). Furthermore, systemic delivery of 5-FC into mice previously injected with CD-transformed spores of C. sporogenes produced greater antitumor effect than maximally tolerated doses of 5-FU. Since most human solid tumors have hypoxic and necrotic areas this vector system has considerable promise for tumor-selective gene therapy.

Original publication

DOI

10.1038/sj.gt.3301659

Type

Journal article

Journal

Gene Ther

Publication Date

02/2002

Volume

9

Pages

291 - 296

Keywords

Animals, Carcinoma, Squamous Cell, Cell Hypoxia, Clostridium, Cytosine Deaminase, Flucytosine, Fluorouracil, Gene Targeting, Genetic Therapy, Genetic Vectors, Mice, Mice, Inbred C3H, Necrosis, Neoplasm Transplantation, Nucleoside Deaminases, Prodrugs